Click Here
if you would like a download of the latest brochure

We are delighted to announce that Andrew Jack, Pharmaceutical Correspondent at The Financial Times will chair the FT Global Pharmaceutical & Biotechnology Conference



 
 


Overview
 

Transformation has become the by-word of an industry suffering the combined effects of patent expirations, declining R&D productivity, and increasing generic competition, but it has also become an imperative if the pharma companies are to survive and thrive in the current economic turmoil, and avoid the growing commoditisation of the industry. The recent wave of M&A is a sign of the accelerating trend, but how successful will the various transformation strategies being pursued and explored by the life science companies be in meeting the challenges the industry faces? What will the life sciences industry look like in a post-crisis world?

The FT Global Pharmaceutical and Biotechnology conference is Europe's pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives, 'feel the pulse' of the industry, and network with peers across the sector. This year's event is no exception and we have assembled a distinguished line-up of industry experts and commentators to share their views and perspective on the key trends that will reshape the life sciences industry for a post -crisis world.

Topics to be addressed at this year's conference include:

  • Transforming the global life sciences industry-the pros and cons of alternative transformation strategies
  • Are diversification strategies merely a side show to the main event-increasing productivity in the lab?
  • Revisiting the pharma-bio innovation equation: the implications of the funding crisis for future innovation in the Industry-crisis or opportunity?
  • Smart regulation-the key to radical transformation?
  • Exploring new avenues for innovation, growth and profitability-the role of emerging markets
  • US healthcare reform and the implications for the global life sciences industry
 
Confirmed Speakers Include:
 
Chris Viehbacher, Chief Executive Officer, Sanofi-aventis
Arthur Higgins, Chairman, Board of Management, Bayer HealthCare AG
Thomas Lönngren, Executive Director, European Medicines Agency (EMEA)
Murray Lumpkin, M.D., Deputy Commissioner for International Programs, US Food and Drug Administration
Lord Paul Drayson of Kensington, Minister of State for Science and Innovation, UK
Harpal Kumar, Chief Executive Officer, Cancer Research UK
Dr Martin Mackay, President Global Research & Development, Pfizer
François Maisonrouge, Senior Managing Director, Evercore Partners
M. Jean-Luc Belingard, Chairman and CEO, Ipsen SA
Kelly Martin,Chief Executive Officer, Elan Corporation
Sigurdur Oli Olafsson, Chief Executive Officer, Actavis
Jonathan Peacock, Chief Financial & Administration Officer, Novartis Pharma AG
Dr Swati Piramal, Vice Chairperson, Piramal Life Sciences Limited